Related Experiment Video

Updated: Jun 13, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

[Diabetes mellitus and prothrombotic activity]

J Malý1

  • 1II. interní klinika Lékarské fakulty UK a FN Hradec Králové. maly@fnhk.cz

Vnitrni Lekarstvi
|May 15, 2010
PubMed

Insights

Diabetic patients face a higher risk of arterial thrombosis due to impaired blood clotting. The REACH study found that antithrombotic treatments were less intensive for diabetic individuals without existing arterial thrombosis symptoms.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Hematology

Context:

  • Diabetes mellitus (DM) significantly increases arterial thrombosis risk, particularly myocardial infarction, due to altered hemostasis and insulin resistance.
  • Obesity in type 2 diabetes exacerbates thrombotic risk through impaired fibrinolysis and a pro-thrombotic state.
  • The REACH study analyzed over 67,000 patients, focusing on arterial thrombosis risk and management.

Purpose:

  • To analyze the intensity of antithrombotic therapy in diabetic patients with and without arterial thrombosis.
  • To investigate treatment differences between patients with ischemic heart disease and diabetes versus those with diabetes alone.

Summary:

  • Multivariate analysis of REACH study data revealed disparities in antithrombotic treatment intensity.
  • Diabetic patients with ischemic heart disease received different treatment intensities compared to those with diabetes only.
  • Notably, antithrombotic therapy was less intensive in diabetic patients lacking clinical signs of arterial thrombosis.

Impact:

  • Highlights potential undertreatment of arterial thrombosis risk in diabetic patients without overt symptoms.
  • Informs clinical practice regarding the necessity of intensified antithrombotic strategies in high-risk diabetic populations.
  • Underscores the link between diabetes, hypercoagulability, and the need for tailored cardiovascular risk management.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.